Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.37 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.36 |
| ▸ | MVD | P53602 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5063580 | 0.89 | FDPS (0.45) | FDPSBLMTDP1BTN3A1ENPP1 | |
| SCHEMBL8534675 | 0.89 | FDPS (0.45) | FDPSBLMTDP1BTN3A1ENPP1 | |
| Triphosphate SCHEMBL15270533 | 0.88 | FDPS (0.56) | FDPSBLMTDP1BTN3A1ENPP1 | |
| SCHEMBL2457995 | 0.87 | FDPS (0.43) | FDPSBLMTDP1BTN3A1ENPP1 | |
| SCHEMBL38363 | 0.85 | FDPS (0.53) | FDPSBLMTDP1BTN3A1ENPP1 | |
| Triphosphate SCHEMBL18714 | 0.84 | FDPS (0.69) | FDPSBLMTDP1BTN3A1MVD | |
| Triphosphate SCHEMBL15555988 | 0.84 | FDPS (0.69) | FDPSBLMTDP1BTN3A1MVD | |
| SCHEMBL5134982 | 0.83 | FDPS (0.39) | FDPSBLMTDP1BTN3A1ENPP1 | |
| SCHEMBL3823202 | 0.82 | FDPS (0.50) | FDPSBLMTDP1BTN3A1ENPP1 | |
| SCHEMBL29225919 | 0.82 | FDPS (0.50) | FDPSBLMTDP1BTN3A1ENPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294924-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-09-05 | — | — | US | disclosed |
| EP-4330397-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022263569-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-12-22 | — | — | WO | disclosed |
| EP-4105328-A1 | ANTISENSE-OLIGONUCLEOTIDES FOR PREVENTION OF KIDNEY DYSFUNCTION PROMOTED BY ENDOTHELIAL DYSFUNCTION BY EPHRIN-B2 SUPPRESSION | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-12-21 | — | — | EP | disclosed |
| US-20220143071-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | Neurovision Pharma GmbH (DE) | 2022-05-12 | — | — | US | disclosed |
| US-11213541-B2 | Antisense-oligonucleotides as inhibitors of TGF-R signaling | Neurovision Pharma GmbH (DE) | 2022-01-04 | — | — | US | disclosed |
| EP-3372684-B1 | SINGLE-STRANDED RNAI AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER | SIRNA THERAPEUTICS INC (US) | 2020-10-07 | — | — | EP | disclosed |
| US-10584335-B2 | Single-stranded RNAi agents containing an internal, non-nucleic acid spacer | SIRNA THERAPEUTICS, INC. (US) | 2020-03-10 | — | — | US | disclosed |
| US-20190314401-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | Neurovision Pharma GmbH (DE) | 2019-10-17 | — | — | US | disclosed |
| US-10363266-B2 | Antisense-oligonucleotides as inhibitors of TGF-R signaling | Neurovision Pharma GmbH (DE) | 2019-07-30 | — | — | US | disclosed |
| WO-2005061710-A1 | OLIGOMERIC COMPOUNDS FOR THE MODULATION OF BCL-2 | SANTARIS PHARMA A/S (DK) | 2005-07-07 | — | — | WO | disclosed |
| EP-1501930-A2 | OLIGOMERIC COMPOUNDS FOR THE MODULATION HIF-1ALPHA EXPRESSION | Santaris Pharma A/S (DK) | 2005-02-02 | — | — | EP | disclosed |
| US-20050014712-A1 | Oligomeric compounds for the modulation survivin expression | ENZON PHARMACEUTICALS, INC | 2005-01-20 | — | — | US | disclosed |
| US-20040248840-A1 | Oligomeric compounds for the modulation of ras expression | SANTARIS PHARMA A/S | 2004-12-09 | — | — | US | disclosed |
| US-20040241717-A1 | Oligomeric compounds for the modulation of thioredoxin expression | SANTARIS PHARMA A/S | 2004-12-02 | — | — | US | disclosed |
| WO-2004069990-A2 | OLIGOMERIC COMPOUNDS FOR THE MODULATION OF THIOREDOXIN EXPRESSION | SANTARIS PHARMA A/S (DK) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004069992-A2 | OLIGOMERIC COMPOUNDS FOR THE MODULATION OF RAS EXPRESSION | SANTARIS PHARMA A/S (DK) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004069991-A2 | OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION | SANTARIS PHARMA A/S (DK) | 2004-08-19 | — | — | WO | disclosed |
| US-20040096848-A1 | Oligomeric compounds for the modulation HIF-1alpha expression | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2004-05-20 | — | — | US | disclosed |
| WO-2003085110-A2 | OLIGOMERIC COMPOUNDS FOR THE MODULATION HIF-1ALPHA EXPRESSION | SANTARIS PHARMA A/S (DK) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143071-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | TGFBR1, TGFBR2, TGFB1 | FDPS 1628/4885BLM 716/4885TDP1 98/4885 |
| US-20040248840-A1 | Oligomeric compounds for the modulation of ras expression | HRAS, KRAS, NRAS | FDPS 3040/4885BLM 473/4885TDP1 1987/4885 |
| US-20040241717-A1 | Oligomeric compounds for the modulation of thioredoxin expression | TXN, TXN2, TXNRD3 | FDPS 3432/4885BLM 1221/4885TDP1 483/4885 |
| US-11213541-B2 | Antisense-oligonucleotides as inhibitors of TGF-R signaling | TGFBR1, TGFBR2, TGFB1 | FDPS 1628/4885BLM 716/4885TDP1 98/4885 |
| US-20040096848-A1 | Oligomeric compounds for the modulation HIF-1alpha expression | HIF1AN, HIF1A, HYOU1 | FDPS 3398/4885BLM 2672/4885TDP1 1461/4885 |
| US-20050014712-A1 | Oligomeric compounds for the modulation survivin expression | BIRC5, XIAP, BIRC3 | FDPS 4342/4885BLM 267/4885TDP1 1514/4885 |
| US-20190314401-A1 | ANTISENSE-OLIGONUCLEOTIDES AS INHIBITORS OF TGF-R SIGNALING | TGFBR1, TGFBR2, TGFB1 | FDPS 1628/4885BLM 716/4885TDP1 98/4885 |
| US-10363266-B2 | Antisense-oligonucleotides as inhibitors of TGF-R signaling | TGFBR1, TGFBR2, TGFB1 | FDPS 1628/4885BLM 716/4885TDP1 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.